Pillar

Curaleaf Reports First Quarter 2024 Results

Retrieved on: 
木曜日, 5月 9, 2024
Pillar, Table, NGC, Net, News, THC, Depreciation, TSX, Public expenditure, Automation, Cannabis, Tax, Senior, Acquisition, MCO, Purchasing, MSO, GAAP, Growth, Earnout, Security (finance)

NEW YORK, May 9, 2024 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today reported its financial and operating results for the first quarter ended March 31, 2024. All financial information is reported in accordance with U.S. generally accepted accounting principles (GAAP) and is provided in U.S. dollars unless otherwise indicated.

Key Points: 
  • First quarter 2024 revenue of $339 million, representing an increase of 2% year-over-year and adjusted gross margin(1) of 48%
    First quarter 2024 adjusted EBITDA(1) of $77 million, representing 23% of revenue, a 40 basis point improvement year-over-year
    NEW YORK, May 9, 2024 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today reported its financial and operating results for the first quarter ended March 31, 2024.
  • Boris Jordan, Executive Chairman of Curaleaf, stated, "Consistent with our expectations, first quarter revenue grew 2% to $339 million, and we achieved a 48% adjusted gross margin.
  • Curaleaf International rebranded Sapphire Clinics to Curaleaf Clinics in the U.K.
    Acquired Can4Med, an experienced pharmaceutical wholesaler in Poland to enhance our market presence.
  • Curaleaf reports its financial results in accordance with GAAP and uses a number of financial measures and ratios when assessing its results and measuring overall performance.

The Honest Company Reports First Quarter 2024 Results

Retrieved on: 
水曜日, 5月 8, 2024
Pillar, Net, Investment, Cosmetics, Skin care, Webcast, Transport, Adjustment, GAAP, Growth, Bank

LOS ANGELES, May 08, 2024 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ: HNST), a personal care company dedicated to creating clean- and sustainably-designed products, today reported financial results for the three months ended March 31, 2024.

Key Points: 
  • Reflects consumption for diapers, wipes, baby personal care, skin care and cosmetics items for latest 12 weeks ended March 24, 2024.
  • The Company ended the first quarter 2024 with $34 million in cash, cash equivalents and short-term investments, an increase of $22 million versus the first quarter of 2023, reflecting disciplined management of working capital.
  • The Company is reaffirming its financial outlook for the full fiscal year 2024 for revenue and Adjusted EBITDA.
  • A webcast and conference call to discuss first quarter 2024 results is scheduled for today, May 8, 2024, at 1:30 p.m. Pacific time/4:30 p.m. Eastern time.

Master the complexities of Pillar Two with our New Online Course!

Retrieved on: 
月曜日, 5月 6, 2024
Pillar, Comprehension, Tax, Learning

Solid grasp of the GloBE Rules: Gain a thorough understanding of Pillar Two's top-up tax, its application scope, and calculation methods.

Key Points: 
  • Solid grasp of the GloBE Rules: Gain a thorough understanding of Pillar Two's top-up tax, its application scope, and calculation methods.
  • Practical application through examples: Master the intricacies of determining GloBE Income or Loss, adjusted covered taxes, and the Qualified Domestic Minimum Top-up Tax (QDMTT) through real-world scenarios.
  • Confidence in navigating Pillar Two: This course equips you with the skills to calculate top-up taxes, identify charging mechanisms, and determine relevant tax components.
  • By enrolling in this course, participants will empower themselves with the expertise needed to navigate the complexities of Pillar Two.

ICPO Foundation awards ICPO Academy stipends to the Department of Nuclear Medicine at Osaka University Hospital

Retrieved on: 
月曜日, 5月 6, 2024
Pillar, PET-CT, Nuclear medicine, Research, Clinic, Curriculum, Medical physics, Nursing, Osaka University Hospital, Principal, ICPO, FAPI, Radiochemistry, Osaka University, Teaching hospital, Thyroid cancer, Health, Associate, Acid test (gold)

Today, the International Centers for Precision Oncology (ICPO) Foundation announced a cooperation with the Department of Nuclear Medicine at the Osaka University Hospital.

Key Points: 
  • Today, the International Centers for Precision Oncology (ICPO) Foundation announced a cooperation with the Department of Nuclear Medicine at the Osaka University Hospital.
  • ICPO offers industry-funded stipends for the ICPO Academy for Theranostics to dedicated healthcare professionals worldwide.
  • "Through this agreement, we have the opportunity to provide advanced training in theranostics to team members of the Department for Nuclear Medicine at Osaka University Hospital.
  • Osaka University Hospital, known for its dedication to excellence, places significant emphasis on research and development in the medical field.

Cache Raises Seed Financing to Advance its Biomolecule Storage Technologies

Retrieved on: 
火曜日, 5月 7, 2024
Technology, Research, Genetics, Health Technology, Biotechnology, Health, Data Management, Other Science, Science, Pillar, Harvard University, University, Cancer, Cache, International Society, American College, Cell, Laboratory, AUC, Harvard Business School, University Health Network, Biological engineering, Genetic, Software, Biophysical environment, Area studies, Biochemistry, RNA, Doctor of Philosophy, University Medical Center, Pathology, San Francisco Bay Area, Intelligence, ACMG, Stanford University, George Church, Bioethics, Chemistry, Faculty, MIT, MBA, SBIR, Yale School of Management, Temperature, Ageing, National Science Foundation, Dicarboxylic acid, Biology, Medical genetics, Nucleation, Computer data storage

Cache DNA, Inc. , a life sciences company revolutionizing biological sample and data storage infrastructure, today announced the closing of its seed round.

Key Points: 
  • Cache DNA, Inc. , a life sciences company revolutionizing biological sample and data storage infrastructure, today announced the closing of its seed round.
  • The funds will help power R&D and support commercial development efforts and key partnerships to bring their solutions to market.
  • “Over the past three decades, sequencing technologies have evolved drastically.
  • It feels like every month, a new sequencing method is developed,” says Michael Becich, Cache CEO.

Target ALS Achieves Extraordinary $250 Million Capital Campaign Goal to Accelerate ALS Research

Retrieved on: 
火曜日, 5月 7, 2024
Pillar, Target, Research, History, Disease, ALS, Diagnosis, Biomarker, Drug discovery, Ecosystem

After his diagnosis with ALS in late 2021, Dan focused his efforts on scaling up Target ALS.

Key Points: 
  • After his diagnosis with ALS in late 2021, Dan focused his efforts on scaling up Target ALS.
  • Equipped with a comprehensive ALS research investment strategy developed by individuals with extensive expertise in ALS, other neurodegenerative diseases, scientific research, and drug discovery, as well as those who have been personally affected by the disease, Dan and the Target ALS team set out to raise awareness and funds to accelerate ALS research.
  • Over the next 8 years, the $250 million will be thoughtfully invested across Target ALS' Seven Pillars, focused on expanding both the breadth and depth of the Target ALS Innovation Ecosystem.
  • This achievement marks an inflection point in the history of ALS research and Target ALS, underscoring an incredible opportunity to drive tangible progress for the ALS community.

Bloomberg Tax & Accounting Recognizes 2023 Federal Authors of The Year

Retrieved on: 
月曜日, 5月 6, 2024
Slate, Pillar, Negotiation, University, Author, Contingent work, Grant Thornton International, IRAS, McDermott Will & Emery, McCarter, Professional corporation, Internal Revenue Service, Health care, Quantity, Financial adviser

ARLINGTON, Va., May 6, 2024 /PRNewswire/ -- Bloomberg Tax & Accounting announced today its 2023 Author Awards for Federal Tax, which were presented in Washington, D.C. Alden Bianchi of McDermott Will & Emery received the Leonard L. Silverstein Award for Distinguished Service in Federal Tax.

Key Points: 
  • ARLINGTON, Va., May 6, 2024 /PRNewswire/ -- Bloomberg Tax & Accounting announced today its 2023 Author Awards for Federal Tax, which were presented in Washington, D.C. Alden Bianchi of McDermott Will & Emery received the Leonard L. Silverstein Award for Distinguished Service in Federal Tax.
  • Federal Tax Portfolio Author of the Year awards were given to the authors of three Portfolios.
  • "We are proud to recognize the exceptional contributions of Alden, Nathan, Moshe, Chase, Brian, Kathryn, Lawrence, and Steven to the field of federal tax," said Lisa Fitzpatrick, president, Bloomberg Tax & Accounting.
  • "These authors exemplify outstanding thought leadership, domain understanding, and dedication that provides Bloomberg Tax's customers with valuable, practical insights and perspectives that help them navigate change.

Top OECD Negotiator, Michael Plowgian, Rejoins KPMG LLP

Retrieved on: 
火曜日, 4月 16, 2024
Pillar, Negotiation, Harvard Law School, Economy, Denison University, KPMG, Organization, Treasury, Tufts University, Diplomacy, Human, Legislation, KPMG LLP, OECD, Renewable energy

New York, New York--(Newsfile Corp. - April 16, 2024) - KPMG LLP, the U.S. audit, tax, and advisory firm, today announced that Michael Plowgian, a leading voice in international tax policy, has rejoined the firm as a principal in Washington National Tax.

Key Points: 
  • New York, New York--(Newsfile Corp. - April 16, 2024) - KPMG LLP, the U.S. audit, tax, and advisory firm, today announced that Michael Plowgian, a leading voice in international tax policy, has rejoined the firm as a principal in Washington National Tax.
  • He will also serve as the International Tax Policy Lead for the Americas and on the Global Policy Leadership Team.
  • "Michael's first-hand experience negotiating at the OECD will be invaluable to our multinational clients grappling with its implementation," said Rema Serafi (@remaserafi), Vice Chair - Tax, KPMG LLP.
  • "The new international tax landscape is extraordinarily complex, with far-reaching impacts on companies' tax positions, compliance, operations and more," said Danielle Rolfes , partner in charge - Washington National Tax, KPMG LLP.

Celestica Announces First Quarter 2024 Financial Results

Retrieved on: 
水曜日, 4月 24, 2024
Pillar, Online, Table, Meeting, EDT, Swings, Suite, Webcast, SBC, Schedule 1, CCS, Celestica, TRS, Legislation, Special, EPS, Yonge Street, Interim

TORONTO, April 24, 2024 (GLOBE NEWSWIRE) -- Celestica Inc. (TSX: CLS) (NYSE: CLS), a leader in design, manufacturing, hardware platform and supply chain solutions for the world's most innovative companies, today announced financial results for the quarter ended March 31, 2024 (Q1 2024)†.

Key Points: 
  • See the tables in Schedule 1 and note 8 to the Q1 2024 Interim Financial Statements for per-item charges.
  • See notes 7, 8 and 9 to the Q1 2024 Interim Financial Statements.
  • Management will host its Q1 2024 results conference call on April 25, 2024 at 8:00 a.m. Eastern Daylight Time (EDT).
  • In addition to disclosing detailed operating results in accordance with IFRS, Celestica provides supplementary non-IFRS financial measures to consider in evaluating the company’s operating performance.

Muscular Dystrophy Association and Friedreich’s Ataxia Research Alliance Announce Collaborative Research Grant Using Novel Gene Editing Technology to Address Root Cause of Friedreich’s Ataxia Disease

Retrieved on: 
水曜日, 4月 17, 2024
Pillar, Enzyme, Friedreich's ataxia, Gene editing, CRISPR, GAA, Hope, Muscular dystrophy, Ataxia, FXN, MDA, Diabetes, FARA, Muscular Dystrophy Association, Column, RNA, Doctor of Philosophy, Research, Scoliosis, Parent, Schnucks, University of Massachusetts, Disease, Therapy, Biomedical Research, Nikolaus Friedreich, Fatigue, Movement, FA, Art, Genome, Organization, Pharmaceutical industry

This funding will further research into using novel genetic technologies to treat Friedreich’s ataxia (FA).

Key Points: 
  • This funding will further research into using novel genetic technologies to treat Friedreich’s ataxia (FA).
  • The grant, Paired Prime Editors to treat Friedreich’s Ataxia, involves prime editing (PE), a next-generation CRISPR gene editing tool that can precisely target the removal of the GAA expansions in the frataxin (FXN) gene.
  • “Our team of investigators is excited to bring multi-disciplinary expertise to the unique challenges of developing PE for FA.
  • This treatment method being targeted – prime editing – aims to directly address the cause of the disease, which is the GAA expansion in the FXN gene.